1. Home
  2. FUND vs IMRX Comparison

FUND vs IMRX Comparison

Compare FUND & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FUND

Sprott Focus Trust Inc.

HOLD

Current Price

$9.62

Market Cap

303.4M

Sector

Finance

ML Signal

HOLD

Logo Immuneering Corporation

IMRX

Immuneering Corporation

HOLD

Current Price

$5.55

Market Cap

265.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUND
IMRX
Founded
1988
2008
Country
Canada
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
303.4M
265.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FUND
IMRX
Price
$9.62
$5.55
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$17.20
AVG Volume (30 Days)
27.0K
1.6M
Earning Date
01-01-0001
05-04-2026
Dividend Yield
6.64%
N/A
EPS Growth
N/A
37.75
EPS
0.93
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.50
$2.90
52 Week High
$10.47
$10.08

Technical Indicators

Market Signals
Indicator
FUND
IMRX
Relative Strength Index (RSI) 41.71 66.60
Support Level $9.31 $5.31
Resistance Level $10.07 $5.80
Average True Range (ATR) 0.16 0.30
MACD 0.00 0.12
Stochastic Oscillator 30.60 95.71

Price Performance

Historical Comparison
FUND
IMRX

About FUND Sprott Focus Trust Inc.

Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, the Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Share on Social Networks: